<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01461837</url>
  </required_header>
  <id_info>
    <org_study_id>NYMC526-4090</org_study_id>
    <secondary_id>FD-R-0004090</secondary_id>
    <nct_id>NCT01461837</nct_id>
  </id_info>
  <brief_title>Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease</brief_title>
  <acronym>HaploSCD</acronym>
  <official_title>Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital &amp; Research Center Oakland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical College of Wisconsin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Miltenyi Biotec GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ann and Robert H. Lurie Children's Hospital of Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>New York Medical College</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to determine the safety and outcome (long-term control) of a
      high-dose chemotherapy regimen followed by an infusion of CD34 selected (immune cells) stem
      cells from a partially matched adult family member donor, called haploidentical stem cell
      transplantation, in high-risk sickle cell disease patients.

      Funding Source - FDA OOPD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate host myeloimmunosuppressive conditioning followed
      by familial haploidentical T cell depleted allogeneic stem cell transplantation in patients
      with high risk Sickle Cell Disease (SCD). It is hypothesized that it will be safe and well
      tolerated, and result in sustained donor chimerism, acceptable engraftment and immune
      reconstitution. Also, that it will limit SCD related organ damage resulting in improved
      and/or stable neurological, neurocognitive, pulmonary and pulmonary vascular function and
      health related quality of life (QOL).

      Patients 2-20.99 years of age with a diagnosis of high-risk SCD and with an unaffected HLA
      partially matched family donor and meeting eligibility criteria (inclusion and exclusion
      criteria) are eligible.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment related events</measure>
    <time_frame>1 year</time_frame>
    <description>Death, primary or late graft rejection, or recurrence of disease and acceptable rate of hematopoietic engraftment, acute and chronic graft-versus-host disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>neurological/neurocognitive status</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline in neurological/neurocognitive status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary/pulmonary vascular status</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline of Pulmonary/pulmonary vascular status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline of Health-related quality of life</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Haplo Stem Cell Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD34 selected T-cell depleted allogeneic SCT</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD34 selected T-cell depleted allogeneic SCT</intervention_name>
    <description>Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0</description>
    <arm_group_label>Haplo Stem Cell Transplantation</arm_group_label>
    <other_name>Familial haploidentical</other_name>
    <other_name>T-cell depleted</other_name>
    <other_name>allogeneic stem cell transplantation</other_name>
    <other_name>high risk Sickle Cell Disease</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous Hemoglobin S Disease, or Hemoglobin S Beta0/+ thalassemia

          -  Patients must demonstrate one or more of the following Sickle Cell Disease
             Complications

               1. Clinically significant neurologic event (stroke) or any neurologic deficit
                  lasting &gt;24 hours that is accompanied by an infarct on cerebral MRI

               2. Minimum of two episodes of acute chest syndrome.

               3. Recurrent painful events (at least 3 in the 2 years prior to enrollment).

               4. Abnormal TCD study requiring starting on chronic transfusion therapy.

               5. At least one silent infarct lesion on a MRI scan of the head.

          -  A familial haploidentical donor without homozygous sickle cell disease

          -  Adequate organ function (renal, liver, cardiac and pulmonary function)

          -  Karnofsky or Lansky (age appropriate) Performance Score â‰¥50%

          -  Liver biopsy is optional to assess for iron overload in chronically transfused
             patients.

        Exclusion Criteria:

          -  Females who are pregnant or breast-feeding

          -  SCD Patients with documented uncontrolled infection

          -  SCD patients who have an unaffected HLA matched family donor willing to proceed to
             donation

          -  Karnofsky/Lansky (age appropriate) Performance Score &lt;50% (hemiplegia alone secondary
             to a previous stroke is not an exclusion)

          -  Demonstrated lack of compliance with medical care.

          -  Clinically significant fibrosis or cirrhosis of the liver

          -  Previously received a HSCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>20 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell S Cairo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mitchell S Cairo, MD</last_name>
    <phone>914-594-2150</phone>
    <email>mitchell_cairo@nymc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Erin Morris, RN</last_name>
    <phone>714-964-5359</phone>
    <email>erin_morris@nymc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California Los Angeles (UCLA)</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Moore, MD</last_name>
      <phone>310-825-6708</phone>
      <email>tbmoore@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>LaMarr Taylor, CCRP</last_name>
      <phone>310-794-8929</phone>
      <email>LaMarrTaylor@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Theodore Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital and Research Center Oakland</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Lurie Children's Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611-2605</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Washington University/St. Louis Children's Hospital</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalini Shenoy, MD</last_name>
      <phone>314-454-6018</phone>
      <email>Shenoy@kids.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Megan Holtmann</last_name>
      <phone>314-454-6018</phone>
    </contact_backup>
    <investigator>
      <last_name>Shalini Shenoy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Valhalla</city>
        <state>New York</state>
        <zip>10595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mitchell S Cairo, MD</last_name>
      <phone>914-594-2150</phone>
      <email>mitchell_cairo@nymc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sandi Fabricatore, RN, PNP</last_name>
      <phone>914-594-2152</phone>
      <email>Fabricatores@wcmc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mitchell S Cairo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin/Children's Hospital of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Talano, MD</last_name>
      <phone>414-955-4185</phone>
      <email>jtalano@mcw.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Jodarski</last_name>
      <phone>414-266-2681</phone>
      <email>kjodarski@chw.org</email>
    </contact_backup>
    <investigator>
      <last_name>Julie Talano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.sicklecelltransplantconsortium.org/</url>
    <description>Consortium website for Parent-to-Child (haplo) Bone Marrow Transplant for Sickle Cell Disease (SCD)</description>
  </link>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2011</study_first_submitted>
  <study_first_submitted_qc>October 26, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 28, 2011</study_first_posted>
  <last_update_submitted>December 14, 2017</last_update_submitted>
  <last_update_submitted_qc>December 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Medical College</investigator_affiliation>
    <investigator_full_name>Mitchell Cairo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>sickle cell disease</keyword>
  <keyword>stem cell transplantation</keyword>
  <keyword>haploidentical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

